A randomized, controlled trial of simvastatin versus rosuvastatin in patients with acute myocardial infarction: the Secondary Prevention of Acute Coronary Events--Reduction of Cholesterol to Key European Targets Trial

Alistair S Hall; Beryl M Jackson; Amanda J Farrin; Maria Efthymiou; Julian H Barth; Joanne Copeland; Kristian M Bailey; Simon P R Romaine; Anthony J Balmforth; Terry McCormack; Andrew Whitehead; Marcus D Flather; Jane Nixon; SPACE ROCKET Trial Group

doi:10.1097/HJR.0b013e3283316ce8

A randomized, controlled trial of simvastatin versus rosuvastatin in patients with acute myocardial infarction: the Secondary Prevention of Acute Coronary Events--Reduction of Cholesterol to Key European Targets Trial

Alistair S Hall
, Beryl M Jackson
, Amanda J Farrin
, Maria Efthymiou
, Julian H Barth
, Joanne Copeland
, Kristian M Bailey
, Simon P R Romaine
, Anthony J Balmforth
, Terry McCormack
, Andrew Whitehead
, Marcus D Flather
, Jane Nixon
, SPACE ROCKET Trial Group

Research output: Contribution to journal › Article › peer-review

21 Citations (Scopus)

Abstract

We sought to evaluate reports that rosuvastatin 10 mg is a more efficacious treatment of hyperlipidaemia than is simvastatin 40 mg, hoping to assess this issue in the previously unstudied context of acute myocardial infarction.

Original language	English
Pages (from-to)	712-21
Number of pages	10
Journal	European Journal of Cardiovascular Prevention and Rehabilitation
Volume	16
Issue number	6
DOIs	https://doi.org/10.1097/HJR.0b013e3283316ce8
Publication status	Published - Dec 2009

Keywords

Aged
Biological Markers
Cholesterol
Cholesterol, LDL
Female
Fluorobenzenes
Great Britain
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hyperlipidemias
Male
Middle Aged
Myocardial Infarction
Odds Ratio
Practice Guidelines as Topic
Prospective Studies
Pyrimidines
Recurrence
Secondary Prevention
Simvastatin
Sulfonamides
Time Factors
Treatment Outcome

Access to Document

10.1097/HJR.0b013e3283316ce8

Cite this

Hall, A. S., Jackson, B. M., Farrin, A. J., Efthymiou, M., Barth, J. H., Copeland, J., Bailey, K. M., Romaine, S. P. R., Balmforth, A. J., McCormack, T., Whitehead, A., Flather, M. D., Nixon, J., & SPACE ROCKET Trial Group (2009). A randomized, controlled trial of simvastatin versus rosuvastatin in patients with acute myocardial infarction: the Secondary Prevention of Acute Coronary Events--Reduction of Cholesterol to Key European Targets Trial. European Journal of Cardiovascular Prevention and Rehabilitation, 16(6), 712-21. https://doi.org/10.1097/HJR.0b013e3283316ce8

Hall, Alistair S ; Jackson, Beryl M ; Farrin, Amanda J et al. / A randomized, controlled trial of simvastatin versus rosuvastatin in patients with acute myocardial infarction : the Secondary Prevention of Acute Coronary Events--Reduction of Cholesterol to Key European Targets Trial. In: European Journal of Cardiovascular Prevention and Rehabilitation. 2009 ; Vol. 16, No. 6. pp. 712-21.

@article{5a174873d3794cf088a09748046fe30f,

title = "A randomized, controlled trial of simvastatin versus rosuvastatin in patients with acute myocardial infarction: the Secondary Prevention of Acute Coronary Events--Reduction of Cholesterol to Key European Targets Trial",

abstract = "We sought to evaluate reports that rosuvastatin 10 mg is a more efficacious treatment of hyperlipidaemia than is simvastatin 40 mg, hoping to assess this issue in the previously unstudied context of acute myocardial infarction.",

keywords = "Aged, Biological Markers, Cholesterol, Cholesterol, LDL, Female, Fluorobenzenes, Great Britain, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hyperlipidemias, Male, Middle Aged, Myocardial Infarction, Odds Ratio, Practice Guidelines as Topic, Prospective Studies, Pyrimidines, Recurrence, Secondary Prevention, Simvastatin, Sulfonamides, Time Factors, Treatment Outcome",

author = "Hall, \{Alistair S\} and Jackson, \{Beryl M\} and Farrin, \{Amanda J\} and Maria Efthymiou and Barth, \{Julian H\} and Joanne Copeland and Bailey, \{Kristian M\} and Romaine, \{Simon P R\} and Balmforth, \{Anthony J\} and Terry McCormack and Andrew Whitehead and Flather, \{Marcus D\} and Jane Nixon and \{SPACE ROCKET Trial Group\}",

year = "2009",

month = dec,

doi = "10.1097/HJR.0b013e3283316ce8",

language = "English",

volume = "16",

pages = "712--21",

journal = "European Journal of Cardiovascular Prevention and Rehabilitation",

issn = "1741-8275",

publisher = "Sage Publications",

number = "6",

}

Hall, AS, Jackson, BM, Farrin, AJ, Efthymiou, M, Barth, JH, Copeland, J, Bailey, KM, Romaine, SPR, Balmforth, AJ, McCormack, T, Whitehead, A, Flather, MD, Nixon, J & SPACE ROCKET Trial Group 2009, 'A randomized, controlled trial of simvastatin versus rosuvastatin in patients with acute myocardial infarction: the Secondary Prevention of Acute Coronary Events--Reduction of Cholesterol to Key European Targets Trial', European Journal of Cardiovascular Prevention and Rehabilitation, vol. 16, no. 6, pp. 712-21. https://doi.org/10.1097/HJR.0b013e3283316ce8

A randomized, controlled trial of simvastatin versus rosuvastatin in patients with acute myocardial infarction: the Secondary Prevention of Acute Coronary Events--Reduction of Cholesterol to Key European Targets Trial. / Hall, Alistair S; Jackson, Beryl M; Farrin, Amanda J et al.
In: European Journal of Cardiovascular Prevention and Rehabilitation, Vol. 16, No. 6, 12.2009, p. 712-21.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - A randomized, controlled trial of simvastatin versus rosuvastatin in patients with acute myocardial infarction

T2 - the Secondary Prevention of Acute Coronary Events--Reduction of Cholesterol to Key European Targets Trial

AU - Hall, Alistair S

AU - Jackson, Beryl M

AU - Farrin, Amanda J

AU - Efthymiou, Maria

AU - Barth, Julian H

AU - Copeland, Joanne

AU - Bailey, Kristian M

AU - Romaine, Simon P R

AU - Balmforth, Anthony J

AU - McCormack, Terry

AU - Whitehead, Andrew

AU - Flather, Marcus D

AU - Nixon, Jane

AU - SPACE ROCKET Trial Group

PY - 2009/12

Y1 - 2009/12

N2 - We sought to evaluate reports that rosuvastatin 10 mg is a more efficacious treatment of hyperlipidaemia than is simvastatin 40 mg, hoping to assess this issue in the previously unstudied context of acute myocardial infarction.

AB - We sought to evaluate reports that rosuvastatin 10 mg is a more efficacious treatment of hyperlipidaemia than is simvastatin 40 mg, hoping to assess this issue in the previously unstudied context of acute myocardial infarction.

KW - Aged

KW - Biological Markers

KW - Cholesterol

KW - Cholesterol, LDL

KW - Female

KW - Fluorobenzenes

KW - Great Britain

KW - Humans

KW - Hydroxymethylglutaryl-CoA Reductase Inhibitors

KW - Hyperlipidemias

KW - Male

KW - Middle Aged

KW - Myocardial Infarction

KW - Odds Ratio

KW - Practice Guidelines as Topic

KW - Prospective Studies

KW - Pyrimidines

KW - Recurrence

KW - Secondary Prevention

KW - Simvastatin

KW - Sulfonamides

KW - Time Factors

KW - Treatment Outcome

U2 - 10.1097/HJR.0b013e3283316ce8

DO - 10.1097/HJR.0b013e3283316ce8

M3 - Article

C2 - 19745745

SN - 1741-8275

VL - 16

SP - 712

EP - 721

JO - European Journal of Cardiovascular Prevention and Rehabilitation

JF - European Journal of Cardiovascular Prevention and Rehabilitation

IS - 6

ER -

Hall AS, Jackson BM, Farrin AJ, Efthymiou M, Barth JH, Copeland J et al. A randomized, controlled trial of simvastatin versus rosuvastatin in patients with acute myocardial infarction: the Secondary Prevention of Acute Coronary Events--Reduction of Cholesterol to Key European Targets Trial. European Journal of Cardiovascular Prevention and Rehabilitation. 2009 Dec;16(6):712-21. doi: 10.1097/HJR.0b013e3283316ce8